These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 24821560)
1. [Observational survey of the French Urological Association evaluating intermittent hormonal modalities treatment in prostate cancer in France]. Salomon L; Ploussard G; Coloby P; Kouri G; Lebret T; Méjean A; Prunet D; Soulié M Prog Urol; 2014 May; 24(6):367-73. PubMed ID: 24821560 [TBL] [Abstract][Full Text] [Related]
2. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer. Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406 [TBL] [Abstract][Full Text] [Related]
3. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153 [TBL] [Abstract][Full Text] [Related]
4. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Calais da Silva F; Calais da Silva FM; Gonçalves F; Santos A; Kliment J; Whelan P; Oliver T; Antoniou N; Pastidis S; Marques Queimadelos A; Robertson C Eur Urol; 2014 Aug; 66(2):232-9. PubMed ID: 23582949 [TBL] [Abstract][Full Text] [Related]
5. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL; J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219 [TBL] [Abstract][Full Text] [Related]
6. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study]. Ouzaid I; Rouprêt M Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913 [TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. Haines IE; Gabor Miklos GL J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918 [TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy. Soga N; Onishi T; Arima K; Sugimura Y Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253 [TBL] [Abstract][Full Text] [Related]
10. Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. Surcel CI; Sooriakumaran P; Briganti A; De Visschere PJ; Fütterer JJ; Ghadjar P; Isbarn H; Ost P; Ploussard G; van den Bergh RC; van Oort IM; Yossepowitch O; Sedelaar JP; Giannarini G; ; BJU Int; 2015 Apr; 115(4):571-9. PubMed ID: 24802335 [TBL] [Abstract][Full Text] [Related]
11. Medical treatment for biochemical relapse after radiotherapy. Quero L; Hennequin C Cancer Radiother; 2014 Oct; 18(5-6):540-4. PubMed ID: 25179255 [TBL] [Abstract][Full Text] [Related]
12. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M; Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491 [TBL] [Abstract][Full Text] [Related]